BindingDB logo
myBDB logout

60 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27597413 58 Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.EBI Southern Medical University
26789933 100 Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.EBI Intra-Cellular Therapies, Inc.
26562545 13 Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.EBI Institute of Radiopharmaceutical Cancer Research
26430878 102 Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate.EBI Washington University School of Medicine
26288344 15 Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).EBI Novartis Institutes for Biomedical Research
25801159 36 Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.EBI CSIR-Indian Institute of Integrative Medicine
24785301 83 Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.EBI AstraZeneca
9873708 12 N-arylrolipram derivatives as potent and selective PDE4 inhibitors.EBI Novartis Horsham Research Center
23421315 18 Novel inhibitors of protein arginine deiminase with potential activity in multiple sclerosis animal model.EBI University Health Network
23260348 91 Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.EBI Janssen-Cilag S.A.
22963052 38 Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.EBI VU University Amsterdam
22891752 18 Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.EBI Universidade Federal do Rio de Janeiro
22889281 36 Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.EBI Novartis Institutes for Biomedical Research
21456625 41 Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).EBI University of Glasgow
18686943 28 Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.EBI Matrix Laboratories Limited
17228876 36 SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.EBI Pfizer Global Research and Development
16168647 80 Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.EBI Merck Frosst Centre for Therapeutic Research
10691693 64 Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.EBI Novartis Pharma AG
12270195 15 Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.EBI Merck Frosst Centre for Therapeutic Research
11755362 16 Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.EBI Novartis Pharma AG
12031319 46 Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.EBI Merck Frosst Centre for Therapeutic Research
21988093 316 Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.EBI Pfizer Inc.
21955943 47 Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.EBI Pfizer Inc.
21983442 142 Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.EBI biocrea GmbH
21871695 46 Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.EBI Rhône-Poulenc Rorer
20933411 69 Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.EBI Merck Frosst Centre for Therapeutic Research
20825218 69 Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.EBI Rhône-Poulenc Rorer
20709547 69 The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.EBI Merck Frosst Centre for Therapeutic Research
20450197 80 Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.EBI Biotie Therapies GmbH
20196613 32 Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).EBI Pfizer Global Research and Development
19631533 126 Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.EBI Pfizer Global Research and Development
19339180 69 The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.EBI Pfizer Global Research and Development
18945617 50 Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI Pfizer Global Research and Development
18835163 41 Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.EBI Merck Frosst Center for Therapeutic Research
16516471 114 Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.EBI Merck Frosst Center for Therapeutic Research
16275071 26 A new chemical tool for exploring the physiological function of the PDE2 isozyme.EBI Pfizer, Inc.
16263279 37 A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.EBI Pfizer, Inc.
12773045 27 Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.EBI Merck Frosst Centre for Therapeutic Research
12749899 15 Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.EBI Merck Frosst Centre for Therapeutic Research
12639571 23 Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.EBI Merck Frosst Centre for Therapeutic Research
12031318 45 CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.EBI Celltech R&D Ltd.
11052785 14 Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).EBI Merck Frosst Centre for Therapeutic Research
10091677 15 Substituted furans as inhibitors of the PDE4 enzyme.EBI Merck Frosst Centre for Therapeutic Research
9873643 60 Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.EBI Novartis Pharma AG
9464356 24 Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.EBI Pfizer Inc.
25283372 27 Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.BDB Northeastern University
19256502 38 Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.BDB Human BioMolecular Research Institute
18243697 77 Identification of a potent new chemotype for the selective inhibition of PDE4.BDB NIH
19464886 30 Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.BDB National Human Genome Research Institute
15715490 145 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyladenine: highly potent and selective PDE4 inhibitors.BDB Purdue Pharma LP
16539372 8 Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.BDB University of North Carolina at Chapel Hill
16183021 19 Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.BDB University of Dundee